10 Best Performing Small-Cap Stocks in 2024

4. ADMA Biologics Inc. (NASDAQ:ADMA)

Year-to-Date Performance as of September 23: 337.94%

Market Cap as of September 23: $4.61 billion

Number of Hedge Fund Holders: 30

ADMA Biologics Inc. (NASDAQ:ADMA) is an end-to-end commercial biopharmaceutical company focused on developing and commercializing plasma-derived therapies. It is dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.

ASCENIV, a flagship product, is a 10% intravenous immune globulin (IVIG) product for treating Primary Humoral Immunodeficiency in adults and adolescents. ASCENIV contributes over 50% to the company’s total revenue. Its current market penetration is less than 3%, but management is confident in its growth potential.

In Q2 2024, the total revenue recorded was $107.19 million, with a 78.29% year-over-year improvement. In addition to the rapid growth of commercial product revenue, this growth was also favored by the accrual reversal related to historically estimated US Medicaid rebates for ADMA’s immunoglobulin products.

Its AI machine learning platform, ADMAlytics, is being expanded to commercial operations. ADMAlytics, implemented earlier this year, has yielded impressive results, including increased production efficiency, enhanced visibility, optimized commercial planning, streamlined plasma pooling, and reduced variability in FTE hours.

The company’s impressive financial results this quarter underscore its strong growth trajectory and potential for further expansion.